Litigation Details for Millennium Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

« Back to Dashboard

Millennium Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Docket		Date Filed	2014-01-22
Court	District Court, D. Delaware	Date Terminated	2019-09-27
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	6,713,446; 6,958,319
Link to Docket	External link to docket

Details for Millennium Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-01-22				External link to document

Millennium Pharmaceuticals v. Teva Pharmaceuticals USA: Litigation Summary and Patent Analysis

Last updated: November 7, 2026

Millennium Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc., No. 1:14-cv-00093, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Teva’s proposed generic version of Velcade, the bortezomib product marketed by Millennium. The dispute centered on patents covering bortezomib and its pharmaceutical use. The case was part of Millennium’s broader effort to delay generic entry before expiration of its Velcade patent estate.

The litigation did not establish a broad, permanent barrier to all generic bortezomib products. Its commercial importance depended on which Orange Book-listed patents Teva challenged, the scope of Teva’s ANDA, and the effective expiration of the asserted claims.

What drug and patents were involved in Millennium v. Teva?

The case involved Velcade, whose active ingredient is bortezomib. Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma. Millennium developed and commercialized the product; Janssen later became associated with its global commercialization.

The principal patent associated with this litigation was U.S. Patent No. 6,713,446, generally directed to boronic acid compounds, including bortezomib, and their pharmaceutical applications. The patent issued in 2004 and had an expiration date in the early 2020s after adjustment and extension calculations. The patent was listed in the FDA Orange Book for Velcade-related products.

Core patent profile

Item	Detail
Brand	Velcade
Active ingredient	Bortezomib
Innovator	Millennium Pharmaceuticals Inc.
FDA category	New drug application product
Primary therapeutic areas	Multiple myeloma; mantle cell lymphoma
Principal patent at issue	U.S. Patent No. 6,713,446
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-00093
Filing year	2014
Litigation type	Hatch-Waxman ANDA litigation
Defendant	Teva Pharmaceuticals USA Inc.

The case should be distinguished from later litigation involving U.S. Patent No. 8,822,438, which covered a specific bortezomib formulation involving mannitol and became the subject of Federal Circuit litigation in Millennium Pharmaceuticals, Inc. v. Sandoz Inc. [1]

Why did Millennium sue Teva?

Teva filed an abbreviated new drug application seeking FDA approval for a generic bortezomib product. The filing triggered a Paragraph IV certification against one or more Orange Book-listed patents. Millennium responded with an infringement action within the statutory 45-day period.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing the certification gives the patent holder the opportunity to sue and creates a statutory 30-month stay of FDA approval under the Hatch-Waxman Act, subject to statutory exceptions and court developments. [2]

Millennium’s objective was to prevent FDA approval of Teva’s ANDA until the relevant patents expired or the litigation ended in Teva’s favor. Teva’s objective was to remove the patent barrier through invalidity, noninfringement, or a settlement permitting an earlier launch.

What were the principal legal issues?

The case presented the standard ANDA issues of infringement and patent validity.

Infringement

The infringement analysis focused on whether Teva’s proposed generic product would practice the asserted patent claims. In ANDA litigation, courts generally examine the product and labeling described in the ANDA rather than a commercial product sold after approval.

For a bortezomib patent, the relevant questions included whether Teva’s proposed product contained the claimed active compound, whether the proposed indications were within the scope of the asserted method claims, and whether the ANDA’s formulation and use instructions met the limitations of any asserted claims.

Invalidity

Teva could challenge the patent on multiple grounds, including:

• Anticipation under 35 U.S.C. § 102.
• Obviousness under 35 U.S.C. § 103.
• Written description and enablement under 35 U.S.C. § 112.
• Patentable subject matter, where applicable.
• Inequitable conduct or unenforceability.

The commercial value of the asserted patent depended on whether its claims covered bortezomib itself, a specific method of treating cancer, or a narrower formulation. Composition claims generally create a stronger generic barrier than method-of-use claims because a generic applicant may attempt a section viii “skinny label” that omits patented indications.

What was the outcome of Millennium v. Teva?

Public case records identify the matter as a patent dispute arising from Teva’s ANDA for generic bortezomib. The case was resolved without a reported trial decision establishing a broad Federal Circuit precedent against Teva. The litigation record should therefore be analyzed separately from the Federal Circuit’s later decision involving Millennium’s bortezomib formulation patent in the Sandoz litigation.

The absence of a widely reported merits opinion in the Teva case limits the amount of publicly available information about the parties’ claim construction positions, expert testimony, and ultimate settlement terms. The case’s practical result was governed by the resolution of the ANDA dispute and the remaining enforceability of the Velcade patent portfolio.

Case-status assessment

Question	Assessment
Was the case an ANDA Paragraph IV action?	Yes
Did Teva seek generic bortezomib approval?	Yes
Was the dispute connected to Velcade patents?	Yes
Was there a reported Federal Circuit merits decision in this specific case?	No broadly reported merits precedent identified
Did the case create a permanent exclusion of all bortezomib generics?	No
Were settlement terms publicly detailed?	Not in a comprehensive public record
Did separate litigation concern Velcade formulation patents?	Yes

What is the Orange Book status of Velcade patents?

Velcade’s patent protection involved several layers:

1. Compound protection for bortezomib.
2. Method-of-use protection for treating specified cancers.
3. Formulation protection for injectable bortezomib products.
4. Regulatory exclusivity and pediatric exclusivity, where applicable.

The Orange Book does not treat every patent in an innovator’s commercial patent portfolio identically. Only patents submitted to FDA and accepted for listing against the relevant NDA appear as Orange Book-listed patents. A patent may remain commercially relevant without creating the same ANDA litigation consequences as an Orange Book-listed patent.

Patent-category comparison

Patent category	Typical effect on generic entry	Relevance to Velcade
Compound patent	Can block the active ingredient directly	High
Method-of-use patent	Can block labeled indications	Depends on label scope
Formulation patent	Can block a specific dosage form or composition	High for injectable products
Manufacturing patent	May create process risk but often does not block ANDA approval directly	Product- and claim-dependent
Non-listed patent	Can support later litigation but does not necessarily trigger a statutory stay	Variable

When did Velcade lose exclusivity?

Velcade’s loss of exclusivity occurred in stages rather than on one date. The relevant milestones included expiration of the core compound patent, expiration of later-issued formulation patents, pediatric exclusivity, and the timing of FDA approval for individual ANDAs.

The U.S. bortezomib market began facing generic competition after the principal patent barriers weakened and generic applicants obtained approval. Several manufacturers ultimately entered or prepared to enter the market, including Teva and other generic drug companies.

The practical launch date for a specific applicant could differ from the nominal patent expiration date because of:

• A litigation settlement.
• A court judgment.
• A license granted by the innovator.
• A forfeiture or non-forfeiture of 180-day generic exclusivity.
• FDA approval timing.
• Manufacturing readiness.
• Regulatory deficiencies unrelated to patent protection.

What formulation patents protected Velcade?

The most significant later formulation patent was U.S. Patent No. 8,822,438. It covered a bortezomib formulation using mannitol and related product characteristics. Millennium asserted the patent against generic applicants, including Sandoz.

In 2017, the Federal Circuit reversed a district court decision that had held the asserted formulation claims obvious. The appellate court found that the prior art did not provide an adequate reason to make the claimed formulation and that the formulation’s unexpected properties supported nonobviousness. [1]

That decision strengthened Millennium’s formulation position against the defendants in that litigation. It did not automatically determine the outcome of every separate Velcade case, including the Teva action.

Why the formulation patent mattered

A formulation patent can remain commercially important after a compound patent expires if:

• The generic applicant seeks approval for the same dosage form.
• The claimed excipients and concentration ranges are difficult to avoid.
• The product’s labeling or ANDA composition falls within the claims.
• The formulation patent remains enforceable after patent-term adjustments or extensions.
• The generic cannot redesign the product without creating regulatory or commercial disadvantages.

For injectable oncology products, formulation patents may have more practical value than method-of-use patents because the approved product composition is often easier to compare against the patent claims.

Did Teva bring a Paragraph IV challenge?

Yes. The litigation arose from Teva’s ANDA and its challenge to Millennium’s listed Velcade patent rights. The Paragraph IV filing created the statutory basis for the infringement action.

A Paragraph IV challenge does not itself prove that a patent is invalid or that the generic will launch. It is a procedural certification that allows the applicant to seek approval before patent expiry and forces the patent holder to defend the listed claims.

Paragraph IV risk factors in the case

Risk factor	Effect
Composition claim covering bortezomib	High barrier to approval or launch
Narrow method-of-use claim	Greater potential for skinny-label approval
Formulation claim matching injectable product	Significant infringement exposure
Weak prior-art record	Improves innovator position
Strong obviousness argument	Improves generic position
Settlement with licensed entry	Converts litigation risk into a timed launch
Multiple patent families	Increases cost and delay for generic applicants

Did Millennium and Teva settle?

The publicly available record does not provide a comprehensive statement of settlement economics or a definitive public description of all commercial terms. Hatch-Waxman settlements commonly include a permitted launch date, a license, an authorized-generic arrangement, restrictions on manufacturing or supply, or a combination of those provisions.

A settlement should not be interpreted as a determination that the patents were valid or infringed. Unless the court enters a merits judgment, the legal outcome remains a negotiated resolution.

Potential settlement terms in this type of dispute include:

• A fixed generic launch date before the latest patent expiration.
• A license limited to certain dosage forms.
• A covenant not to sue.
• Restrictions on the generic’s indications.
• Supply by the innovator or an authorized third party.
• No admission of liability.
• Confidential financial provisions.

The absence of a public merits opinion makes it inappropriate to treat the case as a definitive judicial validation of all Millennium Velcade patents.

Which companies challenged Velcade patents?

Velcade attracted multiple generic challenges because bortezomib became an established oncology product with substantial sales and a relatively concentrated competitive field.

Relevant challengers in Velcade-related litigation included Teva and Sandoz. Other generic applicants may have pursued approval through separate ANDAs and separate patent certifications. Each applicant’s risk profile depended on the formulation, labeling, manufacturing process, and patents identified in its ANDA.

The Sandoz litigation is particularly important because it generated a published Federal Circuit decision concerning the validity of the '438 formulation patent. It should not be conflated with the Teva case merely because both disputes involved Velcade.

How strong was Millennium’s Velcade patent estate?

Millennium’s estate was strongest where it combined a composition claim with formulation claims. The estate was less durable where protection depended only on a narrow method-of-use claim that a generic could potentially omit through a section viii statement.

Strength assessment

Patent layer	Relative strength	Commercial assessment
Core bortezomib composition	High while enforceable	Most direct barrier to generic active ingredient
Injectable formulation	High if claims read on the ANDA	Important after core compound expiration
Cancer treatment method	Moderate to high	Depends on indication and label design
Manufacturing process	Variable	May create infringement exposure without blocking approval
Later patent filings	Variable	Strength depends on written description and obviousness

The Federal Circuit’s decision in the Sandoz matter supported the validity of the asserted formulation claims under the record before that court. [1] It did not eliminate ordinary invalidity and noninfringement defenses in other Velcade cases.

What generic launch scenarios existed?

Three launch scenarios were commercially plausible.

Launch after patent expiration

A generic company could wait until the relevant patents expired and obtain approval without relying on a litigation settlement. This approach reduces litigation exposure but forfeits earlier market entry.

Launch under a settlement license

Teva could receive a contractually permitted launch date before the latest patent expiration. The launch date would depend on the settlement terms and any regulatory restrictions.

At-risk launch

A generic could launch before final resolution of all patent issues if it believed the patents were invalid, unenforceable, or not infringed. An at-risk launch exposes the company to damages, enhanced damages, an injunction, and substantial market disruption if the innovator prevails.

For an oncology injectable, at-risk launch risk is particularly material because manufacturing capacity, hospital contracts, reimbursement status, and inventory commitments can create losses beyond ordinary tablet-generic economics.

What regulatory and commercial factors affected the case?

FDA patent litigation was only one component of the entry analysis. The generic also needed an approvable ANDA, compliant manufacturing sites, validated sterile production, and a commercially viable supply chain.

Bortezomib is an injectable oncology product. Generic competition therefore faced barriers that differ from those for oral solid dosage forms:

• Sterile manufacturing requirements.
• Complex quality-control testing.
• Stability and reconstitution data.
• Hospital and specialty-distributor procurement.
• Limited product volumes relative to mass-market drugs.
• Potential shortages if manufacturing capacity is constrained.
• Formulation similarity requirements.

These factors could delay or reduce the commercial impact of a patent victory. A generic applicant may win the legal dispute but still face limited market penetration if only a small number of qualified manufacturers exist.

How does the Teva case compare with the Sandoz Velcade litigation?

Issue	Millennium v. Teva	Millennium v. Sandoz
Case number	1:14-cv-00093	Separate litigation
Product	Generic bortezomib	Generic bortezomib
Principal focus	Velcade patent challenge involving Teva’s ANDA	Bortezomib formulation patent
Published Federal Circuit precedent	No comparable widely cited merits decision	Yes
Key patent associated with reported appellate ruling	U.S. Patent No. 6,713,446 and related Velcade rights	U.S. Patent No. 8,822,438
Main legal lesson	ANDA dispute and patent-entry risk	Formulation nonobviousness and unexpected results
Commercial implication	Teva-specific entry risk	Broader validation of a formulation patent against the litigated defendants

The two proceedings support a portfolio-level conclusion: Millennium relied on overlapping patent layers, but each layer required separate proof and could produce a different litigation outcome.

What patent litigation affects generic bortezomib today?

The principal historical risk involved expiration and enforceability of the relevant Velcade patents, not a permanent prohibition on generic bortezomib. Once the key patents expired or became commercially ineffective, the market shifted toward generic competition.

For current diligence, the relevant questions are:

1. Which Velcade patents were listed for the specific dosage form?
2. Which patents were challenged by each ANDA applicant?
3. Did the applicant use a Paragraph IV certification or section viii statement?
4. Was entry authorized by settlement?
5. Did the generic obtain final FDA approval?
6. Are any formulation, manufacturing, or pediatric protections still relevant?
7. Are there supply or regulatory constraints independent of patent rights?

Key Takeaways

• Millennium v. Teva, No. 1:14-cv-00093, was a Delaware Hatch-Waxman case involving Teva’s proposed generic bortezomib product.
• The litigation formed part of Millennium’s broader effort to protect Velcade through compound, method-of-use, and formulation patents.
• Teva’s Paragraph IV certification triggered the infringement action and the statutory patent-litigation framework.
• The case should not be conflated with Millennium’s later Sandoz litigation involving U.S. Patent No. 8,822,438.
• The Sandoz appeal produced an important Federal Circuit ruling upholding the nonobviousness of the asserted bortezomib formulation claims on the record presented.
• Publicly available materials do not provide a comprehensive account of the commercial terms of any Teva resolution.
• Generic entry depended on patent expiry, settlement rights, FDA approval, sterile manufacturing capability, and the scope of each applicant’s ANDA.
• Velcade’s patent estate was strongest where composition and formulation claims overlapped with the generic product.

FAQs

What was Millennium Pharmaceuticals v. Teva Pharmaceuticals USA about?

It was a Hatch-Waxman patent case involving Teva’s ANDA for generic bortezomib, the active ingredient in Velcade.

What is the case number for the Velcade Teva litigation?

The case number is 1:14-cv-00093 in the U.S. District Court for the District of Delaware.

Was U.S. Patent No. 8,822,438 the main patent in the Teva case?

The '438 patent is associated primarily with separate bortezomib formulation litigation, including Millennium v. Sandoz. It should not automatically be treated as the principal patent in the Teva action.

Can a generic launch bortezomib with a skinny label?

Potentially. A section viii statement may permit approval for unpatented uses if the generic labeling omits patented indications and the remaining product claims do not cover the proposed product.

Why are injectable bortezomib patents commercially important?

Injectable formulation claims can make product redesign difficult, while sterile manufacturing, stability, reconstitution, and hospital procurement requirements can limit generic competition even after a patent challenge succeeds.

References

1. Millennium Pharmaceuticals, Inc. v. Sandoz Inc., 862 F.3d 1356 (Fed. Cir. 2017).

2. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

4. Millennium Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA Inc., No. 1:14-cv-00093, U.S. District Court for the District of Delaware.